SwePub
Tyck till om SwePub Sök här!
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Fatouros Bergman Helena) "

Sökning: WFRF:(Fatouros Bergman Helena)

  • Resultat 1-10 av 32
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Kaufmann, Tobias, et al. (författare)
  • Common brain disorders are associated with heritable patterns of apparent aging of the brain
  • 2019
  • Ingår i: Nature Neuroscience. - : Nature Publishing Group. - 1097-6256 .- 1546-1726. ; 22:10, s. 1617-
  • Tidskriftsartikel (refereegranskat)abstract
    • Common risk factors for psychiatric and other brain disorders are likely to converge on biological pathways influencing the development and maintenance of brain structure and function across life. Using structural MRI data from 45,615 individuals aged 3-96 years, we demonstrate distinct patterns of apparent brain aging in several brain disorders and reveal genetic pleiotropy between apparent brain aging in healthy individuals and common brain disorders.
  •  
2.
  • Malmqvist, Anna, et al. (författare)
  • Increased peripheral levels of TARC/CCL17 in first episode psychosis patients
  • 2019
  • Ingår i: Schizophrenia Research. - : ELSEVIER. - 0920-9964 .- 1573-2509. ; 210, s. 221-227
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Evidence for a link between the pathophysiology of schizophrenia and the immune system is mounting. Altered levels of chemokines in plasma have previously been reported in patients with schizophrenia under antipsychotic medication. Here we aimed to study both peripheral and central chemokine levels in drugnaive or short-time medicated first episode psychosis (FEP) patients. Method: We analyzed nine chemokines in plasma and CSF from 41 FEP patients and 22 healthy controls using electrochemiluminescence assay. Results: In plasma four chemokines; TARC/CCL17, eotaxin/CCL11, MDC/CCL22, IP-10/CXCL10 and in CSF one chemokine; IP-10/CXCL10 showed reliable detection in N50% of the cases. FEP patients displayed increased levels of TARC/CCL17 in plasma compared to healthy controls, 89.6 (IQR 66.2-125.8) pg/mL compared to 48.6 (IQR 28.0-71.7) pg/mL (p = 0.001). The difference was not attributed to confounding factors. Plasma TARC/CCL17 was not associated with PANSS, CGI or GAF scores, neither with cognitive functions. The chemokines eotaxin/CCL11, MDC/CCL22, IP-10/CXCL10 in plasma and IP-10/CXCL10 in CSF did not differ between FEP patients and controls. Conclusion: In line with a previous study showing that chronic patients with schizophrenia display increased plasma TARC/CCL17 levels, we here found an elevation in FEP patients suggesting a role of TARC/CCL17 in early stages of schizophrenia. The exactmechanism of this involvement is still unknown and future longitudinal studies as well as studies of central and peripheral chemokine levels would be of great interest. (C) 2018 Elsevier B.V. All rights reserved.
  •  
3.
  • Alnaes, Dag, et al. (författare)
  • Brain Heterogeneity in Schizophrenia and Its Association With Polygenic Risk
  • 2019
  • Ingår i: JAMA psychiatry. - : AMER MEDICAL ASSOC. - 2168-6238 .- 2168-622X. ; 76:7, s. 739-748
  • Tidskriftsartikel (refereegranskat)abstract
    • ImportanceBetween-individual variability in brain structure is determined by gene-environment interactions, possibly reflecting differential sensitivity to environmental and genetic perturbations. Magnetic resonance imaging (MRI) studies have revealed thinner cortices and smaller subcortical volumes in patients with schizophrenia. However, group-level comparisons may mask considerable within-group heterogeneity, which has largely remained unnoticed in the literature. ObjectivesTo compare brain structural variability between individuals with schizophrenia and healthy controls and to test whether respective variability reflects the polygenic risk score (PRS) for schizophrenia in an independent sample of healthy controls. Design, Setting, and ParticipantsThis case-control and polygenic risk analysis compared MRI-derived cortical thickness and subcortical volumes between healthy controls and patients with schizophrenia across 16 cohorts and tested for associations between PRS and MRI features in a control cohort from the UK Biobank. Data were collected from October 27, 2004, through April 12, 2018, and analyzed from December 3, 2017, through August 1, 2018. Main Outcomes and MeasuresMean and dispersion parameters were estimated using double generalized linear models. Vertex-wise analysis was used to assess cortical thickness, and regions-of-interest analyses were used to assess total cortical volume, total surface area, and white matter, subcortical, and hippocampal subfield volumes. Follow-up analyses included within-sample analysis, test of robustness of the PRS threshold, population covariates, outlier removal, and control for image quality. ResultsA comparison of 1151 patients with schizophrenia (mean [SD] age,33.8[10.6] years; 68.6% male [n=790] and 31.4% female [n=361]) with 2010 healthy controls (mean [SD] age,32.6[10.4] years; 56.0% male [n=1126] and 44.0% female [n=884]) revealed higher heterogeneity in schizophrenia for cortical thickness and area (t = 3.34), cortical (t=3.24) and ventricle (t range, 3.15-5.78) volumes, and hippocampal subfields (t range, 2.32-3.55). In the UK Biobank sample of 12 490 participants (mean [SD] age,55.9 [7.5] years; 48.2% male [n=6025] and 51.8% female [n=6465]), higher PRS was associated with thinner frontal and temporal cortices and smaller left CA2/3 (t=-3.00) but was not significantly associated with dispersion. Conclusions and RelevanceThis study suggests that schizophrenia is associated with substantial brain structural heterogeneity beyond the mean differences. These findings may reflect higher sensitivity to environmental and genetic perturbations in patients, supporting the heterogeneous nature of schizophrenia. A higher PRS was associated with thinner frontotemporal cortices and smaller hippocampal subfield volume, but not heterogeneity. This finding suggests that brain variability in schizophrenia results from interactions between environmental and genetic factors that are not captured by the PRS. Factors contributing to heterogeneity in frontotemporal cortices and hippocampus are key to furthering our understanding of how genetic and environmental factors shape brain biology in schizophrenia.
  •  
4.
  • Becklén, Meneca, et al. (författare)
  • Plasma bilirubin levels are reduced in first-episode psychosis patients and associates to working memory and duration of untreated psychosis.
  • 2021
  • Ingår i: Scientific Reports. - : Springer Science and Business Media LLC. - 2045-2322. ; 11:1
  • Tidskriftsartikel (refereegranskat)abstract
    • Schizophrenia is a severe mental disorder and one of its characteristics is cognitive impairments. Findings regarding levels of the heme metabolite and plasma antioxidant bilirubin in schizophrenia are inconclusive. However, a recently published study indicate that low levels of bilirubin may be implicated in the memory impairments seen in the disorder. The aim of this cross-sectional study was to investigate the levels of bilirubin in individuals with a first-episode psychosis (FEP) and to examine if bilirubin levels were associated to cognitive impairments, symptoms and duration of untreated psychosis (DUP). Bilirubin levels were reduced in 39 individuals with FEP compared with 20 HC (median [IQR]: 11.0 [9.0-13.0] µM vs. 15.0 [11.5-18.5] µM). In individuals with FEP, bilirubin levels were also positively correlated to two working memory tests (r = 0.40 and r = 0.32) and inversely correlated to DUP (r = - 0.36). Findings were not influenced by confounding factors. The results confirm the antioxidant deficit previously seen in schizophrenia, but also indicate that these changes may be related to DUP. The study also confirms that bilirubin may be implicated in the cognitive deficits that accompanies the disorder, here for the first time presented in individuals with FEP.
  •  
5.
  • Dima, Danai, et al. (författare)
  • Subcortical volumes across the lifespan : Data from 18,605 healthy individuals aged 3-90 years.
  • 2022
  • Ingår i: Human Brain Mapping. - : Wiley. - 1065-9471 .- 1097-0193. ; 43:1, s. 452-469
  • Tidskriftsartikel (refereegranskat)abstract
    • Age has a major effect on brain volume. However, the normative studies available are constrained by small sample sizes, restricted age coverage and significant methodological variability. These limitations introduce inconsistencies and may obscure or distort the lifespan trajectories of brain morphometry. In response, we capitalized on the resources of the Enhancing Neuroimaging Genetics through Meta-Analysis (ENIGMA) Consortium to examine age-related trajectories inferred from cross-sectional measures of the ventricles, the basal ganglia (caudate, putamen, pallidum, and nucleus accumbens), the thalamus, hippocampus and amygdala using magnetic resonance imaging data obtained from 18,605 individuals aged 3-90 years. All subcortical structure volumes were at their maximum value early in life. The volume of the basal ganglia showed a monotonic negative association with age thereafter; there was no significant association between age and the volumes of the thalamus, amygdala and the hippocampus (with some degree of decline in thalamus) until the sixth decade of life after which they also showed a steep negative association with age. The lateral ventricles showed continuous enlargement throughout the lifespan. Age was positively associated with inter-individual variability in the hippocampus and amygdala and the lateral ventricles. These results were robust to potential confounders and could be used to examine the functional significance of deviations from typical age-related morphometric patterns.
  •  
6.
  • Eren, Feride, et al. (författare)
  • Immunological protein profiling of first-episode psychosis patients identifies CSF and blood biomarkers correlating with disease severity
  • 2023
  • Ingår i: Brain, behavior, and immunity. - : Elsevier. - 0889-1591 .- 1090-2139. ; 111, s. 376-385
  • Tidskriftsartikel (refereegranskat)abstract
    • Background and HypothesisImmune activation is suggested to play an important role in psychosis. In this study, a large number of immune-related proteins were analyzed to obtain a more comprehensive picture of immune aberrations in schizophrenia.Study DesignNinety-two immune markers were analyzed by the Olink Protein Extension Assay (Inflammatory Panel) in plasma and cerebrospinal fluid (CSF) from 77 first-episode psychosis (FEP) patients (of which 43 later received the diagnosis of schizophrenia) and 56 healthy controls, all recruited from the Karolinska Schizophrenia Project (KaSP), Stockholm, Sweden.Study ResultsDifferential analysis showed that 12 of 92 inflammatory proteins were significantly higher in the plasma of FEP patients (n = 77) than in controls, and several proteins were positively correlated with disease severity. Patients from the same cohort diagnosed with schizophrenia (n = 43), showed significantly higher levels of 15 plasma proteins compared to controls whereas those not receiving this diagnosis showed no significant differences. The presently used OLINK inflammatory panel allowed the detection of only 47 CSF proteins of which only CD5 differed between patients and controls.ConclusionsThe levels of several peripheral immune markers, particularly those interfering with WNT/β-catenin signaling, were significantly higher in patients with FEP than in healthy controls and associated with illness severity.
  •  
7.
  •  
8.
  • Fatouros Bergman, Helena, 1973- (författare)
  • Emotional interplay and communication with patients diagnosed with schizophrenia
  • 2009
  • Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
    • Emotional interplay and communication with patients diagnosed with schizophrenia was studied in clinical interviews. Fifty-one video recorded interviews were conducted by two psychologists with nine patients. Qualitative and quantitative methods were used in three successive studies. Study I examined the communicative interplay on an overall level, including verbal and nonverbal means of communication. The interviewer’s willingness to explore and pursue the emotional content in the patient’s narrative was found to be important for establishing well functioning communication. In Study II, the stability over time of facial affective expressions in the emotional interplay was evaluated, using EMFACS. For the patients, no substantial changes in the amount of affects were found across all the interview occasions, although for one interviewer, contempt slightly increased. Whereas previous findings found contempt to be the most frequent affect in patients, in the present material disgust was as common, but depended on the interviewer. Study III investigated gaze behaviour and facial affective expressiveness. The objective was to test whether patients reduced their negative facial affectivity during mutual gaze. The patients were found to not reduce their negative facial affectivity during the state of mutual gaze. This finding was independent of both interview occasion and interviewer and implies that the patients might have intended to communicate negative facial affectivity to the interviewer. The research suggests that the emotional interplay is dominated by the negative facial affective expressions of mainly disgust and contempt. It is proposed that these negative affects may be connected to a patient’s low self-esteem, as the self in schizophrenia may be engrained by self-disgusting and self-contemptive affective experiences. The interviewer’s capacity to respond to these negative facial expressions must therefore be considered as important.
  •  
9.
  • Fatouros Bergman, Helena, et al. (författare)
  • Interplay of gaze behaviour and facial affectivity in schizophrenia
  • 2011
  • Ingår i: Psychosis. - : Taylor & Francis Group. - 1752-2439 .- 1752-2447. ; 3:2, s. 148-150
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Some patients diagnosed with schizophrenia display reduced amounts of negative facial affectivity during mutual gaze in everyday conversations with non-professionals. Aims: The aim was to confirm this finding in clinical interviews. Method: Thirty-two video-recorded clinical interviews were conducted with eight patients diagnosed with schizophrenia. Selected sequences were coded for gaze behaviour and facial affective behaviour. Results: During mutual gaze, the patients showed as much negative facial affectivity as expected by chance. Previous findings were not confirmed. Conclusions: Findings suggests that the type of interview has importance for the facial affectivity in patients diagnosed with schizophrenia during mutual gaze.
  •  
10.
  • Fatouros-Bergman, Helena, et al. (författare)
  • Meta-analysis of cognitive performance in drug-naive patients with schizophrenia
  • 2014
  • Ingår i: Schizophrenia Research. - : Elsevier BV. - 0920-9964 .- 1573-2509. ; 158:1-3, s. 156-162
  • Tidskriftsartikel (refereegranskat)abstract
    • Cognitive deficits represent a significant characteristic of schizophrenia. However, a majority of the clinical studies have been conducted in antipsychotic drug treated patients. Thus, it remains unclear if significant cognitive impairments exist in the absence of medication. This is the first meta-analysis of cognitive findings in drug-na ve patients with schizophrenia. Cognitive data from 23 studies encompassing 1106 patients and 1385 controls published from 1992 to 2013 were included. Tests were to a large extent ordered in cognitive domains according to the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) battery. Analysis was performed with STATA using the random-effects model and heterogeneity as well as Egger's publication bias was assessed. Overall the results show that patients performed worse than healthy controls in all cognitive domains with medium to large effect sizes. Verbal memory, speed of processing and working memory were three of the domains with the greatest impairments. The pattern of results is in line with previous meta-analytic findings in antipsychotic treated patients. The present meta-analysis confirms the existence of significant cognitive impairments at the early stage of the illness in the absence of antipsychotic medication.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 32
Typ av publikation
tidskriftsartikel (30)
doktorsavhandling (1)
forskningsöversikt (1)
Typ av innehåll
refereegranskat (29)
övrigt vetenskapligt/konstnärligt (3)
Författare/redaktör
Fatouros-Bergman, He ... (29)
Cervenka, Simon (21)
Erhardt, Sophie (16)
Sellgren, Carl M (13)
Agartz, Ingrid (9)
Piehl, Fredrik (9)
visa fler...
Orhan, Funda (9)
Flyckt, Lena (8)
Farde, Lars (7)
Schwieler, Lilly (7)
Alnæs, Dag (6)
Westlye, Lars T (6)
Andreassen, Ole A (6)
Werbart, Andrzej (6)
Doan, Nhat Trung (6)
Engberg, Goran (5)
Engberg, Göran (5)
Wang, Lei (4)
Bertolino, Alessandr ... (4)
Meyer-Lindenberg, An ... (4)
Pergola, Giulio (4)
Malmqvist, Anna (4)
Franke, Barbara (3)
Ching, Christopher R ... (3)
Canales-Rodríguez, E ... (3)
McDonald, Colm (3)
Pomarol-Clotet, Edit ... (3)
Radua, Joaquim (3)
Salvador, Raymond (3)
Sarró, Salvador (3)
Thompson, Paul M (3)
Schalling, Martin (3)
Kaufmann, Tobias (3)
van der Meer, Dennis (3)
Rokicki, Jaroslav (3)
Moberget, Torgeir (3)
Barch, Deanna M. (3)
Di Giorgio, Annabell ... (3)
Jonsson, Erik G. (3)
Collste, Karin (3)
Nyberg, Lars, 1966- (3)
Jahanshad, Neda (3)
Crespo-Facorro, Bene ... (3)
James, Anthony (3)
Tordesillas-Gutierre ... (3)
Stein, Dan J (3)
de Zubicaray, Greig ... (3)
Ehrlich, Stefan (3)
Espeseth, Thomas (3)
Glahn, David C. (3)
visa färre...
Lärosäte
Karolinska Institutet (26)
Uppsala universitet (21)
Stockholms universitet (10)
Umeå universitet (3)
Göteborgs universitet (2)
Lunds universitet (2)
visa fler...
Linnéuniversitetet (1)
visa färre...
Språk
Engelska (27)
Odefinierat språk (3)
Svenska (2)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (24)
Samhällsvetenskap (6)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy